It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: AVoiceOfReason
a reply to: ExNihiloRed
you dont sell what people cant buy. its that simple. check again. this is a symptom of government.
originally posted by: AVoiceOfReason
a reply to: Phage
no i meant test as in figure out whats in the drugs. ya know, test kits. and no, clinical trials are how you market a drug. obviously drugs will undergo clinical trials. whose gonna buy a drug thats never been tested? which doctor is gonna give his or her patient a drug thats never been tested? who is gonna sell a drug that might kill someone, you really gonna go to jail for manslaughter for a quick buck that youll never make in the first place since no one is going to buy your untested drug? you could sell chalk in pill form. no one is gonna buy it. people obviously want drugs that work dont they? why would people buy drugs that dont work? is this clicking for you?
i guess you dont have much "truck?" with markets or even common sense for that matter. that puts you on par with university student who dont know alot about anything but they dont do alot of critical thinking in the first place so they are perfectly content with sculpting useless fallacious opinions based solely around a lack of knowledge.
thanks for insulting me. or trying. real mature.
just realized i jumped the gun and kinda went off topic. I shall unleash my fury upon you like the crashing of a thousand waves! Begone, vile man! Begone from me! I am untethered, and my rage knows no bounds!
Why? This is not capitalism. Capitalism is about competition, this company was allowed to take an old drug and have no competition. This is a prime example of why we need capitalism.
The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor.
In response to concerns about pricing, Marathon chief executive Jeffrey Aronin announced that the company would delay its launch.
"We have not sold any new product, and we will pause that process," Aronin wrote in a statement posted by the advocacy group CureDuchenne.
Patients will continue to have access to imported drug, according to the statement, and can still apply to an expanded access program offered by the company to get the drug free. He said that the company would meet with caregivers and "move forward with commercialization based on an agreed plan of action."